Spike Protein Articles & Analysis: Older
25 news found
To name just a few here: carrier RNA, RNAse inhibitor, deoxynucleotide triphosphates, guanidine hydrochloride, SARS-CoV-2 Spike Protein (RBD) Monoclonal Antibody, nitrocellulose membranes, dyed microspheres, and more. ...
In the double-blind, randomized Phase 1 trial, 31 subjects ages 20-62 years received one of nine formulations of autologous dendritic cells and lymphocytes (DCL) incubated with 0.10, 0.33, or 1.0 μg of recombinant SARS-CoV-2 spike protein, and then admixed with saline or 250 or 500 μg of granulocyte-macrophage colony-stimulating factor (GM-CSF). ...
Immundiagnostik's respiratroy PCR assays MutaPLEX® Coronavirus (KG1926), MutaPLEX® RespiraScreen 1 (KG1927), MutaPLEX® RespiraScreen 2 DIFF (KG1928) and MutaPLEX® Coronavirus 4G (KG1936) were screened for the spike protein mutations in the following viral variants: [Omicron] (BA.1, BA.2, BA.4, BA.5) [Omicron] (BA.3, BA.2 + L452X) [Alpha], ...
The Omicron variant carries more than 30 spike protein mutations versus previous variants such as Delta. These changes are associated with increased infectivity and confer the potential to evade the host antibody immune response induced by previous vaccinations or infections (“escape mutations”). ...
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, ...
IBIO123 is a cocktail containing 3 recombinant human monoclonal antibodies that specifically bind to distinct regions of the SARS-CoV-2 (COVID-19) spike protein. Data demonstrated highly effective in vitro neutralization of all SARS-CoV-2 VOCs tested, including D614G, Alpha, Beta, Gamma, Delta and Omicron. ...
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infection Immune memory against conserved nucleoprotein may provide an added advantage over spike-only responses Memory T and B cells persisted for at least 6 months post vaccination Data suggest COVAXIN™ (BBV152) may provide ...
The new study focuses on a liquid injection that consists of ingredients including water; specialized liposomes carrying a synthetically produced version of the spike protein of the COVID-19 virus; and a small amount of sugar, which helps to protect the formula during the freeze-drying process. ...
The scientific community is still trying to understand the virus in many ways and compile useful data. The virus uses the spike protein (S protein) to bind angiotensin-converting enzyme 2 (ACE-2) to cause infection. S protein is a highly glycosylated protein with 22 N-linked and 3 O-linked glycosylation sites. ...
Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is the key antigen in current COVID-19 vaccines. ...
"The COVID-19 vaccine uses SpyBiotech's unique protein "superglue" technology to display the SARS Cov-2 spike protein receptor binding domain on the surface of the Hepatitis-B virus-like particles," stated Chief Executive Officer & Chief Scientific Officer of SpyBiotech, Sumi Biswas. ...
A vaccine antigen (a foreign substance, usually a protein, that induces an immune response) is introduced into the body (most often via an injection), with the intention of stimulating the production of antibodies helpful in fighting off future illness. ...
This variant, called VOC202012/01 (B.1.1.7) is defined by multiple spike protein changes (deletion 69-70, deletion 144, amino acid change N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) as well as by mutations in other genomic regions. ...
” Meissa’s initial preclinical data in nonhuman primates shows MV-014-212 induced a SARS-CoV-2 Spike-specific mucosal IgA response, generated serum neutralizing antibodies against Spike-expressing pseudovirus, and was highly protective against SARS-CoV-2 challenge in the upper and lower respiratory tract. ...
INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...
Proceeds will advance the clinical development of SpyBiotech’s novel vaccine technology platform, based on its proprietary SpyCatcher/SpyTag protein “superglue” technology. SpyBiotech plans to begin a Phase I clinical study of its internal lead candidate, targeting human cytomegalovirus (HCMV), in early 2022. ...
Preclinical research demonstrated that BlueWillow’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein resulted in an extremely high neutralizing antibody response, as well as a superior immunoglobulin A (IgA) response in both serum and lung secretions (BAL) samples in mice compared to intramuscular injection of S-2P adjuvanted with ...
The vaccine candidate uses SpyBiotech’s proprietary SpyCatcher/SpyTag protein “superglue” technology to display the coronavirus spike protein on the surface of Hepatitis B surface antigen (HBsAg) VLPs. HBsAg VLPs are a licensed vaccine with excellent safety and immunogenicity data in humans and which are currently ...
recent papers with really interesting results! Click here to read the full paper on computationally designed VLPs. Results: RBD can be efficiently displayed on the mi3 VLP via SpyTag/SpyCatcher RBD-SpyVLP is reactive to monoclonal antibodies isolated from recovered patients RBD-SpyVLP induces a strong ACE2-blocking and neutralising antibody response in mouse models RBD-SpyVLP is highly ...
Meissa’s COVID-19 vaccine candidate, MV-014-210, was derived by modifying the company’s RSV LAV candidate, MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein. Meissa’s COVID-19 vaccine candidate offers significant potential advantages for global deployment, including needle-free intranasal administration, a ...